583 related articles for article (PubMed ID: 28118723)
1. [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Krásenská M
Klin Onkol; 2016; 29 Suppl 3():S39-49. PubMed ID: 28118723
[TBL] [Abstract][Full Text] [Related]
2. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS
Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
[TBL] [Abstract][Full Text] [Related]
3. [Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications].
Petráková K; Krásenská M; Valík D; Holánek M; Palácová M; Demlová R
Klin Onkol; 2016; 29 Suppl 3():S50-57. PubMed ID: 28118724
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
5. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
[TBL] [Abstract][Full Text] [Related]
6. [Ovarian Ablation in Breast Cancer Patients and the Possibility of Influencing Treatment Side Effects].
Palácová M
Klin Onkol; 2016; 29 Suppl 3():S29-38. PubMed ID: 28118722
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
8. Safety of aromatase inhibitors in the adjuvant setting.
Perez EA
Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
[TBL] [Abstract][Full Text] [Related]
9. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
Mouridsen HT
Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
[TBL] [Abstract][Full Text] [Related]
10. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Morales L; Neven P; Timmerman D; Christiaens MR; Vergote I; Van Limbergen E; Carbonez A; Van Huffel S; Ameye L; Paridaens R
Anticancer Drugs; 2004 Sep; 15(8):753-60. PubMed ID: 15494636
[TBL] [Abstract][Full Text] [Related]
11. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
12. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
13. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
Perez EA
Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
[TBL] [Abstract][Full Text] [Related]
14. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
15. Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
Pistelli M; Mora AD; Ballatore Z; Berardi R
Curr Oncol; 2018 Apr; 25(2):e168-e175. PubMed ID: 29719441
[TBL] [Abstract][Full Text] [Related]
16. Are aromatase inhibitors superior to antiestrogens?
Howell A; Buzdar A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
[TBL] [Abstract][Full Text] [Related]
17. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
Dixon JM
Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
[TBL] [Abstract][Full Text] [Related]
18. Menopausal symptoms and adjuvant therapy-associated adverse events.
Hadji P
Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
[TBL] [Abstract][Full Text] [Related]
19. [New options in adjuvant endocrine therapy in breast cancer].
Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
[TBL] [Abstract][Full Text] [Related]
20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]